MIRA Pharmaceuticals (MIRA) said Friday that preclinical data showed its oral ketamine analog Ketamir-2 achieved a "complete reversal of neuropathic pain in preclinical models."
In preclinical studies, Ketamir-2 showed "superior efficacy" compared with ketamine, the company said, adding that it is on track to submit an investigational new drug application to the US Food and Drug Administration by December.
MIRA Pharmaceuticals said it plans to show an efficacy signal in humans in 2025.
Shares of the company were up 2.8% in recent premarket activity.
Price: 1.1000, Change: +0.03, Percent Change: +2.80
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments